Infusion Laboratory: Protocol 2 (Lisuride) - 3
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate clinical safety issues pertaining to lisuride, to cocaine, and to its interaction in a chronic, crack dependent population, and to determine how pretreatment with lisuride modifies the subjective as well as physiological effects of cocaine.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Outcome Measures
Primary Outcome Measures
- Degree of drug craving []
- History, incidence and amount of drug use []
- Type and severity of stimulant withdrawal symptoms []
- Characterization of study population []
- Population incidence of symptoms of depression, po []
- Frequency and intensity of drug use and sexual beh []
- Evidence of change in neurophysiology and brain ac []
- Evidence of change in subjective responses to coca []
- Clinical physiological response to cocaine challen []
- Degree to which study medication influences change []
Eligibility Criteria
Criteria
Inclusion Criteria:
M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Friends Research Institute | Los Angeles | California | United States | 90025 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
Investigators
- Principal Investigator: Walter Ling, M.D., Friends Research Institute, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NIDA-3-0010-3
- Y01-3-0010-3